Clinical Trial Update: Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer [Phase 1]

View source ↗

Summary

This trial update reports the completion of a Phase 1 study evaluating the safety and tolerability of a PARP inhibitor in combination with gemcitabine for pancr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• PARP inhibitor

Snippet

Sponsor: AstraZeneca | Conditions: Pancreatic Neoplasms | Phase 1 | Status: COMPLETED